GINECO prospective non-interventional PROSPECTYON study: Trabectedin plus pegylated liposomal doxorubicin for platinum-sensitive recurrent ovarian cancer

9Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.

Abstract

Background: Trabectedin and pegylated liposomal doxorubicin (PLD) is an effective combination therapy for platinum-sensitive recurrent ovarian cancer (ROC), particularly for disease relapsing within 6-12 months of platinum therapy. The non-interventional PROSPECTYON study evaluated trabectedin/PLD in French clinical practice. Patients and Methods: Patients with ROC after at least one platinum-based regimen received 1.1 mg/m2trabectedin plus 30 mg/m2PLD every 3 weeks. Efficacy and safety were evaluated in subgroups according to platinum-free interval [6-12 versus ≥12 months (partially or fully platinum sensitive, respectively)]. Results: Recurrent disease was partially platinum-sensitive in 58 patients and fully sensitive in 33 patients treated between July 2014 and June 2016. Patients in both subgroups received a median of six cycles of trabectedin and PLD. The most common grade 3 or more toxicities were haematological. Median progression-free survival was 6 months for both subgroups. Conclusion: Trabectedin/PLD is a valuable treatment option for partially or fully platinum-sensitive ROC.

Cite

CITATION STYLE

APA

Selle, F., Heudel, P. E., Hardy-Bessard, A. C., Pozet, A., Meunier, J., Gladieff, L., … Spaeth, D. (2020). GINECO prospective non-interventional PROSPECTYON study: Trabectedin plus pegylated liposomal doxorubicin for platinum-sensitive recurrent ovarian cancer. Anticancer Research, 40(7), 3939–3945. https://doi.org/10.21873/ANTICANRES.14385

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free